Aurobindo Pharma unit CuraTeQ reports positive Phase 3 data for Xolair biosimilar BP11 in chronic spontaneous urticaria, plans EMA and FDA filings by end of Q2 2026
Aurobindo Pharma unit CuraTeQ reports positive Phase 3 data for Xolair biosimilar BP11 in chronic spontaneous urticaria, plans EMA and FDA filings by end of Q2 2026